These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 33854317)

  • 1. Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies.
    Barabássy Á; Sebe B; Acsai K; Laszlovszky I; Szatmári B; Earley WR; Németh G
    Neuropsychiatr Dis Treat; 2021; 17():957-970. PubMed ID: 33854317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.
    Nasrallah HA; Earley W; Cutler AJ; Wang Y; Lu K; Laszlovszky I; Németh G; Durgam S
    BMC Psychiatry; 2017 Aug; 17(1):305. PubMed ID: 28836957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
    Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
    Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study.
    Cutler AJ; Durgam S; Wang Y; Migliore R; Lu K; Laszlovszky I; Németh G
    CNS Spectr; 2018 Feb; 23(1):39-50. PubMed ID: 28478771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
    Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
    Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
    Citrome L
    Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study.
    Durgam S; Greenberg WM; Li D; Lu K; Laszlovszky I; Nemeth G; Migliore R; Volk S
    Psychopharmacology (Berl); 2017 Jan; 234(2):199-209. PubMed ID: 27807604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
    Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
    J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults.
    Edinoff A; Ruoff MT; Ghaffar YT; Rezayev A; Jani D; Kaye AM; Cornett EM; Kaye AD; Viswanath O; Urits I
    Psychopharmacol Bull; 2020 Sep; 50(4):83-117. PubMed ID: 33012874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
    Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
    J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cariprazine in Three Special Different Areas: A Real-World Experience.
    Gesi C; Paletta S; Palazzo MC; Dell'Osso B; Mencacci C; Cerveri G
    Neuropsychiatr Dis Treat; 2021; 17():3581-3588. PubMed ID: 34908838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy.
    Citrome L
    Neuropsychiatr Dis Treat; 2018; 14():2563-2577. PubMed ID: 30323605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression.
    Citrome L; Yatham LN; Patel MD; Barabássy Á; Hankinson A; Earley WR
    J Affect Disord; 2021 Jun; 288():191-198. PubMed ID: 33915374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of cariprazine for the adjunctive treatment of major depressive disorder: a pooled analysis of phase 2b/phase 3 clinical trials.
    Thase ME; Yeung PP; Rekeda L; Liu M; Varughese S
    Int Clin Psychopharmacol; 2024 Jan; ():. PubMed ID: 38277187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.
    Riccobene T; Riesenberg R; Yeung PP; Earley WR; Hankinson AL
    J Child Adolesc Psychopharmacol; 2022 Oct; 32(8):434-443. PubMed ID: 36282772
    [No Abstract]   [Full Text] [Related]  

  • 20. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy.
    Citrome L
    Adv Ther; 2013 Feb; 30(2):114-26. PubMed ID: 23361833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.